OXFORD, Miss., Jan. 26, 2007 (PRIME NEWSWIRE) -- Modern Technology Corp, a bioscience technology development and acquisition company, announced today its new operations unit, Insight Medical Group, released a White Paper titled "Cancer Theories and Cancer Detection".
The White Paper covers current theories about cancer and the AnuCyte Cancer Detection System.
The White Paper is available for download at the following web link:
http://www.insightmedicalgroup.com/library/IMG_White_Paper.pdf
About the AnuCyte Cancer Detection System
The AnuCyte Cancer Detection System is an automated machine that can rapidly detect any form of cancer. The system accurately identifies cancer at any stage in its development and also identifies healthy cancer-free cells in the same test within the same sample. The system eliminates heretofore unreliable, subjective, and error-prone pathology detection of cancer and delivers an automated and objective measurement of the presence or absence of cancer. The AnuCyte system is the first and only system in the world that uses the measurement of advanced chromosomal imbalance as the primary or sole means of detecting cancer. System testing in collaboration with the Cleveland Clinic and Texas Southwestern University demonstrated AnuCyte to successfully detect cancerous and precancerous cells in hundreds of cervical samples and scores of fine needle aspirates from breast tumors. The company is not aware of any automated system in the world more accurate, or even close to AnuCyte's accuracy.
About AnuCyte's Inventors:
The inventor of the AnuCyte system, Dr. David Rasnick, PhD and his scientific research collaborator, Dr. Peter Duesberg, PhD, have been prominent names internationally for many years for their research and publications. On many occasions both have appeared internationally on television, in magazines, newspapers and scientific publications. Peter Duesberg is author of the widely available book: "Inventing the AIDS Virus." Investors may wish to read a recent article in Newsweek concerning the cancer research of Peter Duesberg:
http://www.msnbc.msn.com/id/14757547/site/newsweek/
In 1970, Peter Duesberg isolated the first cancer gene through his work on retroviruses and mapped the genetic structure of these viruses. This and his subsequent work in the same field resulted in his election to the National Academy of Sciences in 1986. He was also the recipient of a seven-year Outstanding Investigator Grant from the National Institute of Health. He has been invited to become an Honorary Member of the World Innovation Foundation alongside 91 Nobel Laureates. (www.thewif.org.uk)
About Insight Medical Group and Modern Technology Corp
Insight Medical Group, a wholly-owned subsidiary, is a specialized biosciences development company whose mission is to bring world-changing medical technology and research to market in the areas of cancer and AIDS. The AnuCyte Cancer Detection System was invented by Dr. David Rasnick, PhD. The technology behind AnuCyte and the chromosomal imbalance theory is the result of 45 years of combined cancer research by Dr. David Rasnick, PhD and Dr. Peter Duesberg, PhD, who continues his studies on cancer research at the University of California, Berkeley. Modern Technology Corp, a bioscience technology development and acquisition company, builds revenues through a model continuous growth, strategic acquisitions, and commercialization of nascent technology. MODC is a fully-reporting public company with the US Securities and Exchange Commission. For the company's SEC filings, visit www.sec.gov. The company's web address is: http://www.moderntechnologycorp.com
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to those detailed from time to time in the Company's filings with the Securities and Exchange Commission.